Showing results (701-710 of 942) with videos related to

Sort By:
Pageof 95
Multiple Sclerosis and Related Disorders|April 17, 2015
MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic reviewN Makhani, S A Morrow, J Fisk, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2016
Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patientsSeyed-Parsa Hojjat, Charles Grady Cantrell, Rita Vitorino, et al.
Pediatrics|November 22, 2018
Adherence of Newborn-Specific Antibiotic Stewardship Programs to CDC RecommendationsTimmy Ho, Madge E Buus-Frank, Erika M Edwards, et al.
Journal of the American Heart Association|February 19, 2025
In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF TrialNina Nouhravesh, Derek Cyr, Adrian F Hernandez, et al.
BMC Neurology|September 28, 2013
Incidence and prevalence of multiple sclerosis in Europe: a systematic reviewElaine Kingwell, James J Marriott, Nathalie Jetté, et al.
Lancet (London, England)|March 15, 2015
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
Journal of the American Heart Association|May 6, 2020
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 TrialBaris Gencer, Xinmin S Li, Yared Gurmu, et al.
The American Journal of Cardiology|September 8, 2001
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapyJ A de Lemos, D A Morrow, C M Gibson, et al.
Circulation|May 20, 2009
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarctionDavid A Morrow, Stephen D Wiviott, Harvey D White, et al.
American Heart Journal|May 13, 2015
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trialMichelle L O'Donoghue, Ruchira Glaser, Philip E Aylward, et al.
Pageof 95